Dave (DAVE) has had the highest return between 2024 and 2026 by a mid-cap US stock, returning 4,497.1%.
| ASSET | YEARS | % RETURN |
|---|
Dave (DAVE) | 2024-2026 | 4,497.12% |
GeneDx (WGS) | 2024-2026 | 3,405.19% |
Sezzle (SEZL) | 2024-2026 | 3,302% |
AXT (AXTI) | 2024-2026 | 2,304.17% |
Regencell Bioscience (RGC) | 2024-2026 | 1,926.78% |
D-Wave Quantum Inc Common Stock (QBTS) | 2024-2026 | 1,764.77% |
Almonty Industries Inc Common Shares (ALM) | 2024-2026 | 1,429.41% |
Rigetti Computing (RGTI) | 2024-2026 | 1,409% |
Praxis Precision Medicines (PRAX) | 2024-2026 | 1,306.92% |
Aura Minerals Inc Common Shares (AUGO) | 2024-2026 | 1,214.02% |
Trevi Therapeutics (TRVI) | 2024-2026 | 1,005.88% |
Kodiak Sciences (KOD) | 2024-2026 | 1,003.34% |
Sellas Life Sciences (SLS) | 2024-2026 | 935.78% |
Dianthus Therapeutics (DNTH) | 2024-2026 | 919.06% |
Abivax SA American Depositary Shares (ABVX) | 2024-2026 | 917.75% |
Palvella Therapeutics (PVLA) | 2024-2026 | 910.83% |
Definium Therapeutics (DFTX) | 2024-2026 | 895.14% |
Tutor Perini (TPC) | 2024-2026 | 848.34% |
Argan (AGX) | 2024-2026 | 756.94% |
Oruka Therapeutics (ORKA) | 2024-2026 | 740.35% |
Solaris Energy Infrastructure (SEI) | 2024-2026 | 722.47% |
Nektar Therapeutics (NKTR) | 2024-2026 | 687.57% |
Erasca (ERAS) | 2024-2026 | 655.81% |
Arcutis Biotherapeutics (ARQT) | 2024-2026 | 641.64% |
Travere Therapeutics (TVTX) | 2024-2026 | 611.96% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.